Issue №129 · 2026-09-22

Daily Briefing · 2026-09-22

Physicians
Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy

Beacon lights path to FDA approval with pivotal trial win for rare vision loss gene therapy

  • Beacon Therapeutics has found the light in a rare vision loss disease that has left larger companies in the dark. The biotech’s gene therapy for X-linked retinitis pigmentosa (XLRP) successfully improved visual acuity in
FierceBiotech ↗

← All issues

Smillin.

A daily 5-minute brief on AI, devices, and digital tools across physicians, dentistry, pharmacy, physician assistants, nursing, digital health, and Health OS. Read by clinicians.

Smillin

Connect

© 2026 Smillin Healthcare TechTermsPrivacyUSA · Daily 6 AM ET